The Bristol Myers Squibb (BMS)/Celgene GSPT1 degrader (CC-90009) is a CRBN-based molecular glue (CELMoD). It is a clinical candidate in Ph. I for AML and MDS, and in contrast to CC-92480 highlighted last March, spares the primary targets of prior imide drugs (IKZF1/3) and instead selectively degrades GSPT1 ( a target previously identified [...]
< 1 minute read
Nov. 3, 2021
CC-90009: A CRBN-Based GSPT1 Molecular Glue Degrader
CC-90009
CRBN-based GSPT1 molecular glue degrader intravenous agent in Ph. I for AML + MDS from phenotypic screen of CRBN mod library J. Med. Chem., Feb. 16, 2021 Celgene/Bristol Myers Squibb, San Diego, CA
Loading...
